Key result
Empagliflozin improves diastolic dysfunction and LV remodeling in preclinical models of HFpEF.
Why the study?
Does empagliflozin improve diastolic dysfunction and cardiac remodeling in rodent models of HFpEF?
Population
Three rodent models of HFpEF: male Golden Syrian hamsters, C57Bl6N mice, and Spontaneously Diabetic Torii…
Comparison
Empagliflozin 10 mg/kg orally for at least 3 weeks vs Vehicle
Design
Preclinical
Follow-up
at least 3 weeks
Authors
Loading...
Empagliflozin partially alleviates diastolic dysfunction and cardiac remodeling in three distinct rodent models of HFpEF, supporting the use of phenogroup-specific preclinical models for translational research.
Does empagliflozin improve diastolic dysfunction and cardiac remodeling in rodent models of HFpEF?
p-value: p=<0.05
Empagliflozin partially alleviates diastolic dysfunction and cardiac remodeling in three distinct rodent models of HFpEF, supporting the use of phenogroup-specific preclinical models for translational research.
Assaly et al. (2025) studied Heart failure with preserved ejection fraction (HFpEF). Empagliflozin vs. vehicle was evaluated on Cardiac function by echocardiography and invasive hemodynamics (diastolic dysfunction and cardiac remodeling) (p=<0.05). Empagliflozin partially alleviated diastolic dysfunction and improved cardiac remodeling in terms of left ventricle hypertrophy and enlargement (p<0.05) in rodent models of HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: